Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not the a fibrinolysis activator (theophylline nicotinate). Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy.
D000328:Adult; D000368:Aged; D000941:Antigens; D001792:Blood Platelets / Q000187:drug effects*; D002470:Cell Survival; D005169:Factor VIII / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010978:Platelet Factor 4; D010979:Platelet Function Tests; D011412:Propanolamines / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000150:complications; D012008:Recurrence; D013468:Suloctidil / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014463:Ultrasonography; D014812:Vitamin K / Q000037:antagonists & inhibitors; D001620:beta-Thromboglobulin
D000941:Antigens; D011412:Propanolamines; D001620:beta-Thromboglobulin; D014812:Vitamin K; D010978:Platelet Factor 4; D005169:Factor VIII; D013468:Suloctidil